Novo Nordisk invests 8.5 billion Danish kroner in new production facility
In a significant development for Denmark’s life sciences sector, Novo Nordisk has just celebrated the groundbreaking of a new production facility, soon to become a key component of Odense’s growing life science ecosystem. The facility is being built in the dynamic Tietgenbyen industrial district in Odense. Construction of this major production site has just begun and is currently scheduled to be completed in 2027.
Odense part of Novo Nordisk’s growth story
Odense is now a major part of the growth story of Novo Nordisk, with the recent announcement of a major capital project to expand capacity in Denmark. The production facility in Odense is designed to accommodate multiple product types within the rare disease area, such as haemophilia and the 8.5 billion Danish kroner ($1.2 billion) investment is expected to create 400 permanent jobs with an additional 1000 FTE as part of the construction phase.
“I have long dreamed of welcoming Novo Nordisk to Odense, and from the very first contact, the dialogue has been positive, respectful, and professional. Novo Nordisk was founded with a core mission to help people, and I am proud that this mission is now taking root here in Odense. We have an ambitious goal of creating 30,000 new jobs over the next decade, and Novo Nordisk will play a key role in achieving this. The hope is that this investment will have a ripple effect – not only in Odense but across the whole of Funen.”
“It is a great pleasure to be here in Odense, on the island of Funen. Establishing a new site is a rare and unique opportunity—it’s been decades since we last selected a new location. Now, we have arrived in Odense. This is just the beginning. There will be plenty of activity around the factory, and I hope things go so well that we will have the opportunity to expand even further here on Funen.”
Bolstering a Thriving Life Science Ecosystem in Odense
Novo Nordisk’s expansion highlights Odense’s rising status in the global life sciences industry. With robust infrastructure and a thriving ecosystem centered on research and development, the city has become an ideal environment for companies eager to advance medical innovation.
In the past three years, the life sciences and biotech industry in Odense has attracted over €2 billion in investments and created 3,000+ jobs. Novo Nordisk’s move is expected to bring further investment and talent, further strengthening the city’s position as a life sciences hub.
Further information
Lone Krogsbøll
Investment Manager - Biotech & Life Science
I help foreign companies in the biotech and life science industry to establish in Odense and connect them to relevant business partners and opportunities here. My background is in health tech, but I’ve focused on broader life science sectors since 2018.
+45 5177 7344
loak@odense.dk
Connect
